Abstract-To identify the pharmacophore of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen (PSMA), a small analog library was designed and screened for inhibitory potency against PSMA. The design of the lead inhibitor was based upon N-acyl derivatives of endogenous substrate folyl-c-Glu and incorporates a phosphoramidate group to interact with the PSMA catalytic zinc atoms. The scope of the analog library was designed to test the importance of various functional groups to the inhibitory potency of the lead phosphoramidate. The IC 50 for the lead phosphoramidate inhibitor was 35 nM while the IC 50 values for the analog library presented a range from 0.86 nM to 4.1 lM. Computational docking, utilizing a recently solved X-ray crystal structure of the recombinant protein, along with enzyme inhibition data, was used to propose a pharmacophore model for the PSMA active site.
Introduction
A notable discovery in prostate cancer research has been the identification of an over-expressed membrane-bound cell surface protein on prostate cancer cells, namely, prostate-specific membrane antigen (PSMA). PSMA, also known as folate hydrolase I (FOLH1) and glutamate carboxypeptidase II (GCPII), [1] [2] [3] is a 750-amino acid type II membrane glycoprotein 4 and was discovered during the development of the LNCaP cell line; one which retains most of the known features of prostate cancer. 5 Although PSMA is primarily expressed in normal human prostate epithelium, the importance of this enzyme lies with the fact that it is upregulated and strongly expressed in prostate cancer cells, including those of the metastatic disease state. 6 Recent studies have demonstrated PSMA expression in the endothelium of tumor-associated neovasculature of multiple nonprostatic solid malignancies, 7 including metastatic renal carcinoma. 8 As such, it is not surprising that PSMA has attracted a great deal of attention as a target for immunotherapy. [9] [10] [11] [12] In addition to its immunological importance, PSMA is also reported to possess two predominant yet poorly understood enzymatic activities: the hydrolytic cleavage and liberation of glutamate from c-glutamyl derivatives of folic acid 13, 14 and the proteolysis of the neuropeptide N-acetylaspartylglutamate (NAAG). 2 However, recent studies suggest that PSMA plays a regulatory role in angiogenesis. 15 Until recently, 16, 17 no crystal structure of PSMA was available and thus the development of specific inhibitors relied upon rational strategies to identify and exploit binding sites in the structural landscape proximal to the active site. For example, we recently identified the presence of a hydrophobic binding site remote from the catalytic center of PSMA using a series of phenylalkylphosphonamidate derivatives of glutamic acid as hydrophobic probes. 18 In addition, we found that a phenylazobenzoyl derivative of c-diglutamate was substantially equivalent to NAAG as a substrate for PSMA. 18 These results led us to hypothesize that a tetrahedral intermediate analog to the hydrolysis of a N-acyl c-diglutamate should exhibit reasonable inhibitory potency against PMSA. Herein we explore the use of substituted phosphoramidates as transition-state analog inhibitors of PSMA.
Results and discussion
The initial design of a phosphoramidate-based PSMA inhibitor is exemplified by lead compound 1a (Fig. 1 ). This compound incorporates features of endogenous PSMA substrate folyl-c-Glu, namely the L L-Glu residue at P1 0 , a carboxyl substituent at the P1 position, and a benzamide group on the P1-amino terminus. The P1 position contains a serine residue, which is conveniently conjugated to a phosphoramidate functionality, serving as a zinc-binding group for the PSMA active site zinc atoms. Importantly, the phosphoramidate group was positioned to act as a transition-state mimic of the scissile amide bond in folyl-c-Glu.
In addition to phosphoramidate 1a, which most closely resembles the folyl-c-Glu substrate, a series of analogs was also explored in order to examine structural and functional features that may be necessary for PSMA inhibitory activity. To this end, a series of novel compounds (1b-1k), as well as the known inhibitor 2-PMPA (1l) 19 , were prepared and examined for inhibitory potency against purified PSMA (Fig. 2) .
A general method for the synthesis of phosphoramidates 1a-1h is outlined in Scheme 1. N,N-Bis(diisopropylamino)-chlorophosphine 2 was treated with benzyl alcohol to generate O-benzyl substituted phosphine 3. This species was treated with various primary alcohols 4a-4h and diisopropylammonium tetrazolide to generate the dialkoxy substituted phosphines 5a-5h. Next, hydrolysis was mediated by 5-ethylthio-1H-tetrazole to form dialkoxy substituted phosphites 6a-6h. Oxidative coupling with bis-benzyl protected glutamic acid, through the transient phosphoryl-chloride species, leads to protected phosphoramidate species 7a-7h. Each of these protected phosphoramidates was purified by silica gel flash chromatography and appeared to be homogeneous by TLC analysis as well as 1 H and 13 C NMR. Lastly, deprotection was carried out by hydrogenolysis in potassium carbonate buffered solution to form the potassium salts of the final products 1a-1h. We have found phosphoramidates to be quite unstable to acid and that the compounds readily decompose in their protonated forms. As such, the final products were generally isolated as cationic salt forms. To confirm that the compounds would be stable under the conditions of the PSMA inhibition experiments, we monitored the stability of a representative analog (1a) at pH 6.8, 7.4, and 8.6 by 31 P NMR every 15 min for 6 h. No change was observed for 1a at pH 7.4 and 8.6, while at pH 6.8 it underwent hydrolysis to 1i with a half-life of 408 min. Based upon these results, we concluded that the inhibitors would be sufficiently stable under the conditions of the enzyme inhibition assay (pH 7.4). These results are in agreement with our previous findings for simple alkyl phosphoramidates. 20 In general, the primary alcohol building blocks 4a-4h were either commercially available or prepared by simple protecting group attachment (typically benzyl esters) to available species. One exception is the building block 4g, which was generated from the base-mediated opening of b-propiolactone with benzyl alcohol as was previously reported. 21 Another exception was species 4f, which was prepared as shown in Scheme 2. Thus, 4-phenyl-butyric acid (8) was converted to the corresponding dianion by treatment with LDA (2 equiv) and then trapped with formaldehyde 22 to generate b-hydroxy acid 9. Subsequent protection yielded the b-hydroxyl benzyl ester species 4f.
The preparation of compound 1i is outlined in Scheme 3. Protected serine derivative 4a was coupled with a dibenzyl protected phosphoramidite species to generate intermediate 10, which was subsequently oxidized to protected phosphate 7i. This was deprotected under hydrogenolysis conditions to generate the desired phosphate conjugated serine species 1i. Phosphoramidate 1j, phosphate 1k, and racemic phosphonate 1l (aka. 2-PMPA) were prepared as described previously. 19, 20, 23 Once obtained, compounds 1a-1l were assayed for inhibition against purified PSMA (Table 1) as described previously. 24, 18, 25 Screening of this library indicated that two general structural frameworks displayed superior inhibitory potency: intact phosphoramidate peptidomimetics such as 1a and 1b as well as simple P1 0 analogs 1j-1k and 1l (2-PMPA). 19 Despite the lack of additional affinity elements, we hypothesized that the dibasic phosphoryl or phosphonyl motif of the latter three compounds is responsible for their enhanced affinity for PSMA through strong interactions with PSMA's active-site zinc atoms. The des-glutamate analog 1i was void of activity confirming that a C-terminal glutamate residue confers considerable binding specificity for PSMA. Compared to the carboxylate analog 1g, the phenylalkyl phosphoramidate 1h retained significant inhibitory potency against PSMA suggesting that the binding landscape or the N-terminal side of the catalytic center is more favorable toward hydrophobic motifs. With respect to the structure of the lead phosphoramidate peptidomimetic 1a, the stereoisomeric analog 1e confirmed the stereochemical importance of the P1 residue. An interesting effect was observed in cases where secondary benzamides (1a and 1c) were compared with their tertiary congeners (1b and 1d). In the case of the serine derivatives (1a-1b), the presence of an extra amide methyl group induced a marginal decrease in activity, while for the 2-aminoethanol derivatives (1c-1d) the same modification resulted in a more potent inhibitor. As tertiary amides typically exist as mixtures of rotamers, it is possible that the cis and trans forms of 1b and 1d have differential activity against PSMA. Furthermore, this implies that the IC 50 values for these inhibitors are averaged over the populations of cis and trans rotameric forms present in the assay conditions. Given the greatly improved potency of 1d over 1c, and its increased likelihood to partition into the cis rotameric form, we speculate that this rotamer may explain the improved potency of 1d relative to 1c, while the effect may be less pronounced or opposite in the case of 1b relative to 1a.
In order to shed further insight into the complementary interactions of these compounds with the active site landscape, computational docking of three representative inhibitors was carried out employing a recently determined X-ray crystal structure of PMSA. 16 The docking results of N-benzamido serine derived phosphoramidate inhibitor (1a) are depicted in Fig. 3a . The phosphoramidate oxygens form a chelated complex with the active site zinc atoms. The serine acarboxyl interacts with Arg 536 while the attached benzamide group is aligned to make potential p-stacking and hydrophobic interactions with active site tyrosine residues. The docked conformation of ethanolaminelinked phosphoramidate inhibitor (1d) is shown in Fig. 3b . Overall, this inhibitor maintains a conformation consistent with 1a, with the same interactions maintained by the glutamate a-and c-carboxyls, as well as the interactions of the benzamide functionality. An additional interaction between the benzamide carbonyl is made with Arg 536 . A notable difference between inhibitors 1a and 1d is the lack of the serine a carboxyl interaction in 1d, which may explain its significantly decreased potency when compared to compound 1a. Lastly, the docking results of potent phosphorus-conjugate glutamate inhibitor 1j are shown in Fig. 3c . The glutamate c-carboxyl maintains similar interactions as were observed for compounds 1a and 1d. As expected, the a-carboxyl is again poised for interaction with Arg 210 , yet the structure of this compound also allows this functional group to participate in chelated interactions with the active site zinc atoms. This, combined with an extra available phosphoramidate oxygen interaction with zinc, could explain the significantly improved potency of 1j in comparison with inhibitors 1a and 1d. 
Conclusion
A lead phosphoramidate peptidomimetic (1a) was designed to mimic the tetrahedral intermediate of the hydrolysis of a N-acyl diglutamate substrate by PSMA, and was found to be a potent inhibitor of this enzyme. Based upon the structural framework of this inhibitor, a small library of compounds (1b-1k) was prepared to explore the pharmacophore requirements of the PSMA active site. Inhibitory potency was determined for 1a-1k, along with the known inhibitor 2-PMPA (1l). Basic pharmacophore requirements were determined based on the inhibitory data for these compounds, and a tentative mode of binding for inhibitors 1a, 1d, and 1j was suggested based on computational docking studies utilizing a recent crystal structure of PSMA. The development of further optimized inhibitors based upon these conclusions will be reported in due course.
Experimental

Synthesis
All solvents used in reactions and diisopropylethylamine (DIPEA) were both anhydrous and obtained as such from commercial sources. All other reagents were used as supplied unless otherwise stated. Liquid flash chromatography (silica or C18) was carried out using a Biotage 12i/40i system. 1 H, 13 C, and 31 P NMR spectra were recorded on either a Bruker 300 or 500 MHz instrument. 1 Triethylamine (590 lL, 4.18 mmol) and benzyl alcohol (1 equiv) were sequentially added dropwise to a stirred solution of bis(diisopropylamino) chlorophosphine (1 equiv) in anhydrous hexane (35 mL). The reaction mixture was stirred for 3 h at rt, after which the solids were filtered and solvent was removed in vacuo. The residue was immediately dissolved in anhydrous CH 2 Cl 2 (15 mL) and transferred via syringe to a stirred solution of an alcohol (4a-4i) and N,N-diisopropylammonium tetrazolide (0.6 equiv) in CH 2 Cl 2 (20 mL) at 0°C under argon. The reaction mixture was stirred 30 m at rt, after which the solids were filtered and solvent was removed in vacuo. The crude reaction mixture was dissolved in CH 3 CN (30 mL) and cooled to 0°C. A solution of 1-H-tetrazole (1 equiv) in a mixture of distilled H 2 O (1 mL) and CH 3 CN (1 mL) was then added and the reaction mixture stirred for 15 min at 0°C and then 1 h at rt. Solvent was removed in vacuo. The residue was washed twice with 10% HCl (50 mL) and the crude mixture was extracted with EtOAc (50 mL). The organic layer was sequentially washed with 10% NaHCO 3 (50 mL), distilled H 2 O (50 mL), and brine (50 mL). After drying the organic layer with MgSO 4 , the solvent was removed in vacuo to yield the phosphite (6a-6i), typically as an oil, which was used immediately in the next step without characterization or purification.
A solution of glutamic acid dibenzyl ester (0.475 g, 1.45 mmol) in CH 3 CN (6 mL) was added dropwise to a stirred solution of crude phosphite (0.9 equiv) in CH 3 CN (3 mL) and CCl 4 (6 mL) at 0°C under argon. The reaction mixture was stirred for 2 h and solvent was reduced to half its volume in vacuo. The residue was dissolved in CH 2 Cl 2 (40 mL) and sequentially washed with 10% HCl (2 · 40 mL), 10% NaHCO 3 (40 mL), and brine (40 mL). The organic layer was dried over MgSO 4 and concentrated in vacuo to give a yellow oil. The product was isolated by flash chromatography (1:1 hexane/ethyl acetate). Rf % 0.3. The isolated product could be further purified by recrystallization from benzene/cyclohexane (1:5 v/v) to generate benzyl protected phosphoramidates (7a-7h).
General procedure B: Deprotection to generate phosphoramidate inhibitors as potassium salts (1a-1i)
To a solution of a benzyl ester protected phosphoramidate (7a-7h) or phosphate (7i) (0.254 mmol) in THF (2 mL) were added 10% Pd/C (20 mg), K 2 CO 3 (2 equiv), and distilled H 2 O (2 mL). The mixture was stirred vigorously, purged with argon, and hydrogenated overnight at rt. The solvent was removed in vacuo and the residue was dissolved in methanol, filtered through Celite and then through a 0.2 lm PTFE micropore filtration disk (Whatman). Solvent was removed in vacuo to yield a viscous oil (1a-1i). In some compounds, triteration with ethyl acetate could be used to generate products in solid form. 1 H NMR (300 MHz, CDCl 3 ). Note: while isolated as a homogeneous species, 1 H NMR characterization of this compound was complicated due to extensive broadening caused by N-rotomerism in the presence of P-diastereomers. 13 1): d 1.80-1.92 (m, 2H), 2.13-2.24  (m, 2H), 3.06 (s, 1.4H), 3.14 (s, 1.6H), 3.44-3.57 (m,  2H), 3.76-3.84 (m, 2H) , 4.03 (q, 2H, J = 5.7 Hz), 7.44-7.53 (m, 5H). 13 
N-Benzoyl-Ser-[PO
2-Hydroxymethyl-4-phenyl-butyric acid benzyl ester (4f)
Anhydrous THF (20 mL) was cooled to À78°C and treated with LDA (1 M/THF) (12.8 mL, 12.8 mmol). The solution was stirred at À78°C and then a solution of 4-phenyl-butyric acid (1.0 g, 6.09 mmol, 0.48 equiv) in THF (3 mL) was added dropwise over 1 min. The solution was stirred for 5 min, and was then treated with HMPA (2.1 mL), stirred for 5 more minutes at À78°C, and then stirred in an ice bath for 10 min. The reaction mixture was then treated with a stream of anhydrous formaldehyde over a period of $30 min, led in from another reaction vessel containing paraformaldehyde (1.09 g, 36.5 mmol, 6.0 equiv). The reaction mixture was then treated with NH 4 Cl (satd aq), acidified to pH 4, and extracted with EtOAc (3 · 15 mL). The organic layer was dried over Na 2 SO 4 and concentrated in vacuo to yield 2-hydroxymethyl-4-phenyl-butyric acid (9) as a slightly greenish-yellow oil (0.904 g, 76%) which was used in the next step without purification or characterization.
To a solution of crude 2-hydroxymethyl-4-phenyl-butyric acid (9) 
2-Benzoylamino-3-(bis-benzyloxy-phosphoryloxy)-propionic acid benzyl ester (7i)
A mixture of benzoylamino-3-hydroxy-propionic acid benzyl ester (4a) (0.815 g, 2.72 mmol) and 5-ethylthio-1H-tetrazole (0.886 g, 6.8 mmol) was dissolved in CH 3 CN under argon. Then dibenzyl diisopropyl phosphoramidite (2550 lL, 7.75 mmol) was added dropwise via syringe, and the resulting solution was stirred for 9 h. The solution was then oxidized by adding tert-butyl hydroperoxide (3 mL, 21.67 mmol) and stirred for 45 m. The crude product was taken up in CH 2 Cl 2 , washed twice with 10% HCl (50 mL), 10% NaHCO 3 (50 mL), H 2 O (50 mL), brine (50 mL), and then dried over MgSO 4 . The product was isolated by silica gel flash chromatography (1:3 acetone/hexane) as a viscous oil (21%). 1 
